Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

(2021) Jonathan R Strosberg et al.   LANCET ONCOLOGY

Twelve-year Follow-up after Peptide Receptor Radionuclide Therapy (PRRT)

(2018) Michael Gabriel et al.   JOURNAL OF NUCLEAR MEDICINE

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle

(2016) Bernhard Nilica et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

(2016) Anja Rinke et al.   NEUROENDOCRINOLOGY

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

(2015) Irene Virgolini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER